Romosozumab clinical trials
Also written Evenity and AMG 785.
How each study uses romosozumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the romosozumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Apr 2019 · EVENITY · BLA 761062 (FDA, Drugs@FDA)
- European Union
- 9 Dec 2019 · Evenity · EMEA/H/C/004465 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2021 (7); 2 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 7 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 17
Amgen (21) · Tuen Mun Hospital (3) · Memorial Sloan Kettering Cancer Center (2) · Massachusetts General Hospital (2) · Susan L. Greenspan (1) · James J. Peters Veterans Affairs Medical Center (1) · UCB Biopharma SRL (1) · VA Office of Research and Development (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test romosozumab, phase 3 first.
- May 2027Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaPhase 3 · Amgen
- Jan 2027Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsPhase 1 · Amgen
- Mar 2027A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisPhase 1 · Memorial Sloan Kettering Cancer Center
- Mar 2027Romosozumab Use to Build Skeletal IntegrityPhase 4 · Susan L. Greenspan
- Sep 2027Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 YearsPhase 4 · Tuen Mun Hospital
Studies
Open first, then newest update. How each study uses romosozumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Romosozumab and Denosumab Combination Therapy for OsteoporosisNot yet recruitingPhase 4Massachusetts General HospitalNCT07909304Written as Romosozumab
- Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsRecruitingPhase 1AmgenNCT07811999Written as Romosozumab
- A Study of Romosozumab in People With Breast Cancer and OsteoporosisRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07776613Written as Romosozumab
- Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDNot yet recruitingPhase 4Sahlgrenska University HospitalNCT07772609Written as Romosozumab
- Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 YearsNot yet recruitingPhase 4Tuen Mun HospitalNCT07757373Written as Romosozumab
- The Optimised Use of Romozosumab StudyRecruitingPhase 4University of AarhusNCT06059222Written as Romosozumab
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic AmenorrheaRecruitingPhase 3Massachusetts General HospitalNCT06533865Written as Romosozumab
- Romosozumab and Denosumab, Alone or Combined, in Postmenopausal OsteoporosisRecruitingPhase 4National Taiwan University HospitalNCT07283887Written as Romosozumab
- Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility FracturesNot yet recruitingPhase 4Marmara UniversityNCT06720350Written as Romosozumab and Denosumab Combination Therapy
- A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.CompletedPhase 4AmgenNCT06079476Written as Romosozumab
- A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With OsteoporosisCompletedPhase 3UCB Biopharma SRLNCT05067335Written as Romosozumab
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCICompletedPhase 2VA Office of Research and DevelopmentNCT04232657Written as Romosozumab
- Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery OutcomesWithdrawnPhase 2University of PittsburghNCT06973109Written as Romosozumab
- Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingPhase 3AmgenNCT05972551Written as Romosozumab
- Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 MonthsCompletedPhase 4Tuen Mun HospitalNCT06472050Written as Romosozumab
- Romosozumab Use to Build Skeletal IntegrityActive, not recruitingPhase 4Susan L. GreenspanNCT05058976Written as Romosozumab
- A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05775094Written as Romosozumab
- Romosozumab in Women With Chronic SCICompletedPhase 2Northwestern UniversityNCT04708886Written as Romosozumab
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCIActive, not recruitingPhase 4James J. Peters Veterans Affairs Medical CenterNCT05101018Written as Romosozumab
- Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisCompletedPhase 3AmgenNCT01631214Written as Romosozumab
See all 39 studies that test romosozumab →
Given beside what is tested · 3 — romosozumab is usual care or a partner of the new treatment
- Combined Anabolic TherapyRecruitingPhase 4Massachusetts General HospitalNCT06558188Written as Romosozumab
- Anabolic Therapy in Postmenopausal OsteoporosisActive, not recruitingPhase 4Massachusetts General HospitalNCT05010590Written as Romosozumab
- Romosozumab/Denosumab Study for Premenopausal IOPActive, not recruitingPhase 2Columbia UniversityNCT04800367Written as Romosozumab Prefilled Syringe [Evenity]
As the comparator · 2 — what is tested is compared with romosozumab
- Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis PatientsRecruitingPhase 4National Taiwan University HospitalNCT06938152Written as Romosozumab followed by Denosumab
- Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy SubjectsEnrolling by invitationPhase 1Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07384104Written as Romosozumab
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered1
- Romosozumab and Denosumab Combination Therapy for OsteoporosisNov 2, 2026NCT07909304
Codes
What other systems call romosozumab · ClinicalTrials.gg INT005797
- MeSH (NLM) C557282romosozumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3VHF2ZD92JROMOSOZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2123126One source FDA
- Wikidata Q7363297RomosozumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152246RomosozumabOne source FDA
- DrugBank DB11866One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C557282 | romosozumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3VHF2ZD92J | ROMOSOZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2123126 | — | One source FDA |
| Wikidata | Q7363297 | Romosozumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152246 | Romosozumab | One source FDA |
| DrugBank | DB11866 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.